AngioDynamics, Inc. (ANGO)

F4Q10 (Qtr End 05/31/10) Earnings Call

July 15, 2010 02:30 p.m. ET


Doug Sherk - IR

Jan Keltjens - President & CEO

Joe Gersuk - EVP & CFO


Jayson Bedford - Raymond James

Jamar Ismail - Canaccord

Brooks West - Craig-Hallum Capital

Robert Goldman - C.L. King

Thomas Kouchoukos - Stifel Nicolaus

Larry Haimovitch - HMTC



Compare to:
Previous Statements by ANGO
» AngioDynamics, Inc. F3Q10 (Qtr End 02/28/10) Earnings Call Transcript
» AngioDynamics, Inc. F2Q10 (Qtr End 11/30/09) Earnings Call Transcript
» AngioDynamics F1Q10 (Qtr End 9/30/09) Earnings Call Transcript

Ladies and gentlemen, thank you for standing by and welcome to the AngioDynamics Fourth Quarter 2010 Financial Results Conference Call. During today's presentation all parties will placed in a listen only mode. Following the presentation the conference will open for questions. (Operator instructions). This conference is being recorded today, Thursday, July 15th of 2010.

And I would now like to turn the conference over to Doug Sherk. Please go ahead, sir.

Doug Sherk

Thank you for joining us today for the AngioDynamics conference call to review the results of the fiscal fourth quarter and full year which ended on May 31, 2010.

The news release announcing the fourth quarter earnings crossed the wire this afternoon after the market closed and is available on the AngioDynamics website. The call is being broadcast live on the web at A replay of the call will also be archived on the AngioDynamics website.

Before we get started, during the course of this conference call the company will make projections or forward-looking statements regarding future events including the statements about revenue and earnings for fiscal 2011. We encourage you to review the company’s past and future filings with the SEC, including without limitation the company’s Forms 10-Q and 10-K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

In addition, today’s presentation includes certain financial measures used to better understand our business that have not been prepared in accordance with the Generally Accepted Accounting Principles, better known as GAAP. An explanation and reconciliation of these non-GAAP measures has been provided in today’s news release issued by AngioDynamics and is available on the website at

AngioDynamics uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends of the company’s business overtime. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to financial reporting measures prepared in accordance with GAAP.

In today's call, the company has reported non-GAAP EBITDA and EBITDA per share and has reviewed these measures as an internal analysis and review of operation performance.

Finally, during the question-and-answer period today we’d like to request each caller to limit themselves to two questions and encourage callers to re-queue to ask additional questions. We appreciate everyone’s cooperation with this procedure.

And now, I’d like to turn the call over to Jan Keltjens, President and Chief Executive Officer of AngioDynamics.

Jan Keltjens

Thanks, Doug, and good afternoon everyone. Thank you for joining us in our fourth quarter conference call. With me today is Joe Gersuk, our CFO.

There's a lot we like about our fourth quarter financial performance. Top line growth of 14% and operating income growth excluding items of 17%, combined with a rock solid cash flow provided a very strong finish to fiscal 2010. With this performance, we delivered on one of our key objectives for the year which was profitable growth.

The drivers for our fourth quarter was strong revenue growth paired with strong operating expense leverage. These drivers have proven to be more than sufficient to offset the impact of an on-going price environment as well as unfavorable sales mix on our gross margin. Our fourth quarter revenue growth was broad based as all three businesses contributed at 14% our organic growth rate is as strongest as it has been in the last two years.

Engines of growth in Q4 were Varicose Vein products, Micro-introducer kits, LC Beads and last but not least our RF and NanoKnife ablation products. LC Beads still benefited from the competitive product entitled been out of the market this quarter.

We believe the LC Bead growth rate will slowdown from the fourth quarter because this competitive product has returned to the market. However, we also believe that LC Bead should generate positive growth during fiscal 2011.

The partnership at Biocompatibles, the manufacturer of LC Beads continuous to be mutually beneficial and we will be exploring ways to continue this beyond January 1, 2012.

At the same time our shareholder should know that we believe there are a number of scenarios that will allow us to be able to achieve continued profitable growth into calendar year 2010 and beyond.

We are very pleased with the strong performance of a very varicose vein in a healthy market environment which we continue to target about 15% annual growth rate. We continue to gain market share. The combination of a NeverTouch laser fiber platform which was launched a little over 1 year ago and our strong sales force supported by a revamp and broad practice development program is driving solid sales growth.

We believe that through ongoing innovation international expansion and increasing U.S. penetration our VenaCure EVLT franchise will continue to be an engine of growth. We also manage to stabilize our Access revenue in the fourth quarter, this despite the competitive pricing environment.

Our results were aided by launch of both the central split-tip dialysis catheters and a Triple Lumen Smart PICC. Our strategic goal is to obtain a number two position in key segments of the excess market, how we plan to use innovation, corporate accounts and international expansion to drive revenue growth and create economy of scale.

Read the rest of this transcript for free on